Brief: Active Biotech Q2 Operating Loss Narrows To SEK 5.4 Million
08/08/2019 07:38
Aug 8 (Reuters) - Active Biotech AB ACTI.ST :
* REG-ACTIVE BIOTECH AB: INTERIM REPORT JANUARY – JUNE 2019
* Q2 NET SALES SEK 1.1 MILLION VERSUS SEK 5.7 MILLION YEAR
AGO
* Q2 OPERATING LOSS SEK 5.4 MILLION VERSUS LOSS SEK 7.3
MILLION
YEAR AGO
* FIRST HALF OF 2019 HAS PROGRESSED ACCORDING TO PLAN
* WE ARE CONTINUING OUR EFFORTS TO DEVELOP TASQUINIMOD
PROJECT IN
BLOOD CANCER INDICATION MULTIPLE MYELOMA IN COOPERATION WITH
WISTAR INSTITUTE IN PHILADELPHIA
* FOCUS OF THE SILC AND PAQUINIMOD PROJECTS REMAINS DIRECTED
TO
FINDING A DEVELOPMENT PARTNER
* AVAILABLE LIQUIDITY, CAPITAL INFUSION GENERATED BY SALE OF
PROPERTY IN APRIL 2019, AND INCOME FROM PARTNER AGREEMENTS ARE
ASSUMED TO BE SUFFICIENT TO FINANCE OPERATIONS
Source text for Eikon: ID:nGNE4K5fbJ
Further company coverage: ACTI.ST
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))